Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 918-929

  Berdy, Gregg J ^a   Stoppel, Juan O ^a   Epstein, Arthur B ^a  

^a Opthalmology Associates   (United States)

Author keywords

Conjunctival allergen challenge; Loteprednol; Ocular allergy; Olopatadine

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; DIBENZOXEPIN DERIVATIVE; EYE DROPS; LOTEPREDNOL ETABONATE; OLOPATADINE; ALLERGEN; ANTIALLERGIC AGENT; NAPHAZOLINE; PLACEBO;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ACUITY; ALLERGIC REACTION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; MEASUREMENT; PRURITUS; RAGWEED POLLEN; RATING SCALE; SCORING SYSTEM; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADULT; AGED; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0035986660     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80007-8     Document Type: Article

References (36)

1. Epidemiology of hay fever and perennial allergic rhinitis
2. Differential diagnosis of ocular allergic disorders
3. Histamine
4. Ocular antiallergic/anti-inflammatory drugs
5. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: Effects of new topical ocular drugs
6. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs
7. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943 A), an effective anti-allergic/antihistaminic agent
8. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model
9. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model
10. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model
11. Loteprednol etabonate: A review of ophthalmic clinical studies
12. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis
13. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model
14. Intraocular pressure: Measurement, regulation, and flow relationships
15. Molecular mechanisms of steroid action in asthma
16. Antihistamines and antihistamine/vasoconstrictor combinations
17. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases
18. Olopatadine inhibits TNFalpha release from human conjunctival mast cells
19. Antiallergic therapies
20. In vivo effects of corticosteroids on human allergic responses. I. Effects of systemic administration of steroids
21. Inhibition by glucocorticoids of the mast cell-dependent wheal and flare response in human skin in vivo
22. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effect of single allergen challenge
23. The comparison of the efficacy of fluticasone propionate with cetirizine in perennial allergic rhinitis
24. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells
25. Intranasal allergen challenge during corticosteroid treatment
26. Late phase reactions
27. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge
28. Allergen dose response and late symptoms in a human model of ocular allergy
29. Tear and conjunctival changes during the allergen-induced early- and late-phase responses
30. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration
31. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases
32. Conjunctival eosinophils in allergic ocular disease
33. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids